Severity and Mortality Associated with Steroid Use among Patients with COVID-19: A Systematic Review and Meta-AnalysisReview Article Published on 2021-05-062022-10-29 Journal: Interdisciplinary Perspectives on Infectious Diseases [Category] COVID-19, [키워드] 95% CI 95% confidence interval all-cause mortality articles CINAHL CIs Cochrane Library condition Corticosteroid corticosteroid therapy Corticosteroids COVID-19 COVID-19 patient COVID-19 patients Critically ill determine Evidence Google infected with COVID-19 information Meta-analysis Mortality no significant difference outcome Patient patients with COVID-19 performed random effect reduction reduction in mortality Result review risk ratio RRs severe disease severity Significant significant difference steroid use treat treated Treatment treatment group use of steroid was collected window [DOI] 10.1155/2021/6650469 PMC 바로가기 [Article Type] Review Article
The association of estimated cardiorespiratory fitness with COVID-19 incidence and mortality: A cohort studyResearch Article Published on 2021-05-052022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] 95% confidence interval age approach aRR association cardiorespiratory cohort study covariates COVID-19 CRF death determine develop died eCRF examined finding group ICD-10 identify incidence individual moderate participant PCR tests positive prospective cohort study Protective risk risk ratio severe COVID-19 illness Sex significantly significantly lower suggested tested UK biobank virus while with COVID-19 [DOI] 10.1371/journal.pone.0250508 PMC 바로가기 [Article Type] Research Article
Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials코로나19 환자에서 하이드록시클로로퀸의 사망률, 바이러스 제거 및 기타 임상 결과: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-05-012022-09-11 Journal: Clinical and translational science [Category] SARS, 임상, [키워드] 95% CI 95% confidence interval adverse events certainty certainty of evidence Clinical outcome clinical outcomes coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection database effective Efficacy evaluated Evidence HCQ Hydroxychloroquine IMPROVE increased risk Lower Meta-analysis Mortality MOST no effect no significant effect not effective observational studies Patient patients with COVID-19 Prevent prevention of COVID-19 Prophylaxis Randomized controlled trial Randomized controlled trials RCT RCTs reducing mortality risk risk difference risk ratio safety profile screened searched systematic review Treatment Trial viral clearance [DOI] 10.1111/cts.13001 PMC 바로가기 [Article Type] Meta-Analysis
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialCOVID-19로 병원에 입원한 환자의 토실리주맙(RECOVERY): 무작위, 통제, 공개 라벨, 플랫폼 시험Clinical Trial Published on 2021-05-012022-08-13 Journal: Lancet (London, England) [Category] Fulltext, SARS, 임상, 진단, [키워드] (Medical Research Council 1:1 28-day mortality 95% CI Adult patients baseline benefit C-reactive protein clinical outcomes composite endpoint Corticosteroids COVID-19 therapy death died discharged dose eligible enrolled evaluate the effect Evidence evidence of finding funding hospital hospitalised hospitalised COVID-19 patient hospitalised COVID-19 patients hypoxia Innovation intention-to-treat population intravenously Invasive mechanical ventilation ISRCTN less Medical Research Council not improved Open-label oxygen oxygen saturation Oxygen therapy Patient Platform trial Primary outcome random assignment randomised Randomised Evaluation rate ratio receiving RECOVERY trial Registered respiratory Respiratory Support risk risk ratio second dose Standard of care subgroups of patients survival systemic corticosteroids systemic inflammation the patient Tocilizumab Treatment Trial trial participant usual care weight with COVID-19 [DOI] 10.1016/S0140-6736(21)00676-0 PMC 바로가기 [Article Type] Clinical Trial
Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trialsCOVID-19 환자에서 하이드록시클로로퀸과 클로로퀸의 사용: 무작위 임상 시험의 메타 분석Meta-Analysis Published on 2021-05-012022-09-11 Journal: Pathogens and global health [Category] SARS, 임상, 치료제, [키워드] 95%CI adverse effect adverse effects antimalarial association Azithromycin Chloroquine clinical recovery Clinical studies clinical study Cochrane Library control group coronavirus COVID-19 COVID-19 patients disease health problem Hydroxychloroquine in vitro study inclusion criteria increase in LILACS Meta-analysis Mortality Patient patients treated patients with COVID-19 public health randomized clinical trial randomized clinical trials risk risk ratio SARS-CoV-2 searched shown significant effect survival systematic review target the patient Treatment virological cure with COVID-19 [DOI] 10.1080/20477724.2021.1884807 PMC 바로가기 [Article Type] Meta-Analysis
Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points주요 업데이트: COVID-19 성인을 위한 Remdesivir : American College of Physicians Practice Points를 위한 살아있는 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-05-012022-09-11 Journal: Annals of internal medicine [Category] Fulltext, SARS, 치료제, [키워드] assessment baseline benefit Bia clinically college controlled trials coronavirus disease Coronavirus disease 2019 Course COVID-19 decrease Department development disease severity Effect Evidence Final GRADE greater hospital Hospitalized IMPROVE include increase in Major mechanical ventilation Meta-analysis moderate Mortality New outcomes Patient patients with COVID-19 physician Point Practice proportion Randomized controlled trial RCT RCTs receiving reduce reduce mortality reduction in reduction in mortality Remdesivir review risk risk ratio Serious Adverse Event Serious Adverse Events severity Time to recovery Treatment Ventilation veteran were used with COVID-19 [DOI] 10.7326/M20-8148 PMC 바로가기 [Article Type] Meta-Analysis
An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients중증 COVID-19 환자에서 클로로퀸/하이드록시클로로퀸의 효능을 평가하는 공개 라벨 무작위 대조 시험Clinical Trial Published on 2021-04-272022-08-13 Journal: Scientific Reports [Category] MERS, SARS, 임상, 치료제, [키워드] 105 patient 105 patients 9-point ordinal scale acute renal dysfunction acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 added Administered all-cause mortality analyzed arrythmia Arrythmias Brazil cardiovascular complication cardiovascular complications Chloroquine chloroquine/hydroxychloroquine Clinical outcome clinical status Combination coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 doubt drugs Effect Effects Efficacy enrolled evaluate FIVE Follow-up form hospital Hydroxychloroquine incidence increased risk intention to treat intervention group Invasive mechanical ventilation KDIGO mITT Odds ratio once daily Open-label Ordinal Scale outcomes Patient patients hospitalized positive RT-PCR Primary outcome randomization Randomized Randomized controlled trial Registered renal dysfunction respiratory risk risk ratio Sample size SARS-CoV-2 secondary outcome severe acute respiratory syndrome Coronavirus severe COVID-19 severe COVID-19 patient severe renal dysfunction standard care standard treatment the disease Treatment Trial Trial registration were assessed worsening [DOI] 10.1038/s41598-021-88509-9 PMC 바로가기 [Article Type] Clinical Trial
The COVID-19 pandemic and new clinical trial activationsCOVID-19 전염병 및 새로운 임상 시험 활성화Research Published on 2021-04-082022-09-10 Journal: Trials [Category] MERS, 임상, [키워드] 95% CI Activation Analysis association Cancer Cancer clinical trials Cancer patients cardiovascular Cardiovascular clinical trials Care caused changed Clinical research clinical trial ClinicalTrials.gov consequence COVID-19 COVID-19 outbreak COVID-19 pandemic death diagnose Diseases Drug discovery examined expected initial landscape less mental health Mental health clinical trials Non-COVID-19 occurred oncology outbreak pace pandemic patients Poisson regression question rebound reduction in Relative risk relative risk ratio Research Result resulting retrospective cohort study risk risk ratio Trial USA was used Winter [DOI] 10.1186/s13063-021-05219-3 PMC 바로가기 [Article Type] Research
Spatial and temporal trends in social vulnerability and COVID-19 incidence and death rates in the United StatesResearch Article Published on 2021-03-242022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] average Bayesian center Community conducted Control COVID-19 COVID-19 incidence COVID-19 outbreak Daily temperature death rate death rates Effect examined female Health Hierarchical higher risk index less longitudinal analysis pandemic physician prevention primary care proportion quartile quartiles Result reversed risk ratio RRs Smokers tested the United State USAFacts vulnerability [DOI] 10.1371/journal.pone.0248702 PMC 바로가기 [Article Type] Research Article
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysisCOVID-19 환자의 회복기 혈장 치료와 임상 결과의 연관성: 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-03-232022-09-11 Journal: JAMA [Category] 임상, [키워드] 95% CI all-cause mortality Analysis assessment assessment tool benefit Bia certainty Characteristics clinical Clinical deterioration Clinical improvement Clinical outcome clinical outcomes conducted convalescent plasma convalescent plasma treatment COVID-19 data extraction decrease development Evidence hazard ratio Hospital stay Inclusion inverse Limited mechanical ventilation Meta-analysis moderate Mortality no significant differences Other outcomes outcome outcomes Patient peer-reviewed Placebo plasma platform press primary analysis randomized clinical trial randomized clinical trials RCT RCTs Release releases review risk risk difference risk ratio searched selected Serious Adverse Event Serious Adverse Events significant differences significantly Standard of care synthesis Treatment treatment effects treatment for COVID-19 Trial [DOI] 10.1001/jama.2021.2747 PMC 바로가기 [Article Type] Meta-Analysis